United Kingdom · Question · Written question
UIN 113161
Voluntary Scheme for Branded Medicines Pricing and Access
Introduced
19 December 2022
Last action
9 January 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
9 January 2023
Summary
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the impact of changes to the Voluntary Scheme for Branded Medicines Pricing Access (VPAS) rebate on (a) clinical trials investment in the UK and (b) the priori
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
19 December 2022
Written question
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the impact of changes to the Voluntary Scheme for Branded Medicines Pricing Access (VPAS) rebate on (a) clinical trials investment in the UK and (b) the priori
Source: Commons
9 January 2023
Answer
The impact of higher payment percentages in both the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), and the Statutory Scheme on research and development investment, on the prioritisation of the United Kingdom as launch market for innova...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-12-19/113161
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1563152
- uk · wq-1563152 · source updated 9 January 2023